Prothena Corporation PLC (PRTA) Holdings Boosted by Swiss National Bank

Swiss National Bank raised its position in Prothena Corporation PLC (NASDAQ:PRTA) by 2.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 63,600 shares of the biotechnology company’s stock after buying an additional 1,300 shares during the quarter. Swiss National Bank owned about 166,144.20% of Prothena Corporation PLC worth $4,119,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Birchview Capital LP bought a new position in Prothena Corporation PLC in the 3rd quarter valued at about $235,000. American Century Companies Inc. increased its holdings in Prothena Corporation PLC by 16.5% in the 3rd quarter. American Century Companies Inc. now owns 23,982 shares of the biotechnology company’s stock valued at $1,553,000 after buying an additional 3,398 shares during the period. Westpac Banking Corp bought a new position in Prothena Corporation PLC in the 3rd quarter valued at about $1,373,000. Parametrica Management Ltd bought a new position in Prothena Corporation PLC in the 3rd quarter valued at about $307,000. Finally, First Trust Advisors LP bought a new position in Prothena Corporation PLC in the 3rd quarter valued at about $212,000.

Shares of Prothena Corporation PLC (PRTA) opened at $45.85 on Friday. Prothena Corporation PLC has a one year low of $44.43 and a one year high of $70.00.

Prothena Corporation PLC (NASDAQ:PRTA) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.41) by $0.04. Prothena Corporation PLC had a negative net margin of 562.19% and a negative return on equity of 34.40%. The company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.28 million. During the same period last year, the company posted ($1.26) EPS. The firm’s quarterly revenue was down 33.6% compared to the same quarter last year. research analysts forecast that Prothena Corporation PLC will post -4.27 earnings per share for the current fiscal year.

In other news, Director Dennis J. Selkoe sold 3,500 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $64.17, for a total value of $224,595.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Tara Nickerson sold 17,500 shares of the firm’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $63.60, for a total transaction of $1,113,000.00. Following the completion of the sale, the insider now owns 19,500 shares in the company, valued at $1,240,200. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 29,424 shares of company stock worth $1,922,787. 3.10% of the stock is currently owned by corporate insiders.

PRTA has been the topic of several recent analyst reports. Wedbush lowered shares of Prothena Corporation PLC from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $75.00 to $55.00 in a report on Monday. Deutsche Bank AG set a $73.00 target price on shares of Prothena Corporation PLC and gave the company a “buy” rating in a report on Monday, October 23rd. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $70.00 target price on shares of Prothena Corporation PLC in a report on Thursday, November 9th. Cantor Fitzgerald reissued a “buy” rating and issued a $79.00 target price on shares of Prothena Corporation PLC in a report on Thursday, September 28th. Finally, ValuEngine lowered shares of Prothena Corporation PLC from a “hold” rating to a “sell” rating in a report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and thirteen have given a buy rating to the company’s stock. Prothena Corporation PLC presently has an average rating of “Buy” and a consensus target price of $76.75.

TRADEMARK VIOLATION NOTICE: This article was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://sportsperspectives.com/2017/11/24/prothena-corporation-plc-prta-holdings-boosted-by-swiss-national-bank.html.

Prothena Corporation PLC Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Want to see what other hedge funds are holding PRTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prothena Corporation PLC (NASDAQ:PRTA).

Institutional Ownership by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply